National_Coverage_Determinations_Manual / 220.6.15

Subscribe or sign in to view the full article.

articles:    previous index next
Note:  The following article synopsis was NOT provided by HCPro. It was created by Find-A-Code/innoviHealth.

Article Overview

This National Coverage Determinations Manual entry explains Medicare’s coverage approach for FDG PET in cancer indications not previously specified. It outlines the general coverage-with-evidence-development framework, the types of prospective clinical studies referenced, and where CMS says information about available services will be published. The article is relevant to oncology, nuclear medicine, imaging providers, compliance staff, and coding teams monitoring Medicare coverage policy updates.

Why This Topic Matters

Coverage policy affects whether services are considered payable under Medicare and how providers must track participation in qualifying studies and documentation requirements. Understanding this NCD helps organizations align billing, utilization management, and clinical trial-related workflows with current CMS policy.

Article Sections

  1. FDG PET for All Other Cancer Indications Not Previously Specified

    Introduces the coverage policy for FDG PET in cancer indications not previously addressed elsewhere in the manual. Summarizes the effective date and the overall coverage framework.

  2. Coverage with Evidence Development

    Describes the general conditions under which coverage with evidence development applies and identifies the broad study characteristics referenced by CMS. Focuses on the policy structure for prospective clinical studies and related participation requirements.

  3. Medicare Notification and Access Information

    Notes how Medicare indicates providers and beneficiaries will be informed about where services can be accessed. References CMS communication channels for policy availability.

What You Will Learn

  • The scope of Medicare coverage for FDG PET in other cancer indications
  • How the article frames coverage with evidence development
  • The general types of clinical studies referenced by the policy
  • Where CMS says access information for these services will be posted

Who Should Read This

  • Medical coders
  • Billing and reimbursement staff
  • Compliance teams
  • Oncology providers
  • Nuclear medicine and imaging departments
  • Utilization management staff
  • Health information professionals

Subscribe or sign in to view the full article.

Official DecisionHealth® Newsletter Archives includes:

  • Includes over 25,000 articles from:
    • Coder Pink Sheets
    • Part B News
    • Answer Books newsletters
  • Current newsletters added each quarter
  • Timely news and guidance vital for your practice
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to the Find-A-Code Code Information pages
  • Code Information pages link back to related articles
  • Save yourself tons of research time, find everything in one place!
Access to this feature is available in the following products:
  • DecisionHealth Coding, Billing and Compliance Library

Related Articles

Articles are listed in order of calculated relevance.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.

Aimee- AI -powered coding assistant - Try it now for Free Would you like Aimee - AI
to help you with this?